E Fund Management Co. Ltd. Buys Shares of 2,870 Spero Therapeutics, Inc. (NASDAQ:SPRO)

E Fund Management Co. Ltd. bought a new stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,870 shares of the company’s stock, valued at approximately $42,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. D.A. Davidson & CO. increased its position in shares of Spero Therapeutics by 1.7% during the 4th quarter. D.A. Davidson & CO. now owns 30,000 shares of the company’s stock valued at $582,000 after purchasing an additional 500 shares during the last quarter. Banque Cantonale Vaudoise increased its position in shares of Spero Therapeutics by 150.0% during the 4th quarter. Banque Cantonale Vaudoise now owns 2,000 shares of the company’s stock valued at $39,000 after purchasing an additional 1,200 shares during the last quarter. Sentinel Pension Advisors Inc. increased its position in shares of Spero Therapeutics by 11.8% during the 1st quarter. Sentinel Pension Advisors Inc. now owns 26,410 shares of the company’s stock valued at $425,000 after purchasing an additional 2,795 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Spero Therapeutics by 25.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 15,000 shares of the company’s stock valued at $221,000 after purchasing an additional 3,000 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Spero Therapeutics by 34.4% during the 4th quarter. American International Group Inc. now owns 11,885 shares of the company’s stock valued at $230,000 after purchasing an additional 3,045 shares during the last quarter. 64.17% of the stock is owned by hedge funds and other institutional investors.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Spero Therapeutics in a research report on Tuesday, June 1st. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $30.00.

Spero Therapeutics stock opened at $15.79 on Friday. The business has a 50 day moving average price of $13.77. The stock has a market cap of $468.41 million, a price-to-earnings ratio of -5.18 and a beta of 1.54. Spero Therapeutics, Inc. has a 12-month low of $8.50 and a 12-month high of $23.64.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, May 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.05). The firm had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $2.71 million. Spero Therapeutics had a negative return on equity of 65.11% and a negative net margin of 498.66%. On average, sell-side analysts expect that Spero Therapeutics, Inc. will post -3.07 EPS for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Read More: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Want to see what other hedge funds are holding SPRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spero Therapeutics, Inc. (NASDAQ:SPRO).

Institutional Ownership by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.